Life ScienceCompany
GamaMabs Pharma - AMHR2 Antibody Technology Ownership
Who owns GamaMabs Pharma - AMHR2 Antibody Technology?
GamaMabs Pharma - AMHR2 Antibody Technology is owned by Exelixis. It was acquired on May 4, 2021.
GamaMabs Pharma - AMHR2 Antibody Technology Business Overview
Where is GamaMabs Pharma - AMHR2 Antibody Technology headquartered?
GamaMabs Pharma - AMHR2 Antibody Technology is headquartered in Toulouse, France.
What sector is GamaMabs Pharma - AMHR2 Antibody Technology in?
GamaMabs Pharma - AMHR2 Antibody Technology is a life science company.
Life Science M&A Summary in 2021
Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.
Join Mergr to view all 398 acquisitions of life science companies in 2021, including 46 acquisitions by private equity firms, and 352 by strategics.